Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients
Abstract
:1. Introduction
2. Material and Methods
2.1. Donors’ Selection
2.2. Patients’ Selection
2.3. COVID-19 Convalescent Plasma
2.4. Laboratory Tests
2.5. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Shen, C.; Wang, Z.; Zhao, F.; Yang, Y.; Li, J.; Yuan, J.; Wang, F.; Li, D.; Yang, M.; Xing, L.; et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020, 323, 1582–1589. [Google Scholar] [CrossRef]
- Perotti, C.; Baldanti, F.; Bruno, R.; Del Fante, C.; Seminari, E.; Casari, S.; Percivalle, E.; Glingani, C.; Musella, V.; Belliato, M.; et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica 2020, 105, 2834–2840. [Google Scholar] [CrossRef]
- Axfors, C.; Janiaud, P.; Schmitt, A.M.; Hooft, J.V.; Smith, E.R.; Haber, N.A.; Abayomi, A.; Abduljalil, M.; Abdulrahman, A.; Acosta-Ampudia, Y.; et al. Association between convalescent plasma treatment and mortality in COVID-19: A collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect. Dis. 2021, 21, 1170. [Google Scholar] [CrossRef]
- WHO Recommends Against the Use of Convalescent Plasma to Treat COVID-19. Available online: https://www.who.int/news/item/07-12-2021-who-recommends-against-the-use-of-convalescent-plasma-to-treat-covid-19#:~:text=Convalescent%20plasma%20is%20a%20transfusion,while%20it%20has%20significant%20costs (accessed on 1 April 2022).
- IDSA Guideline on the Management and Treatment of COVID-19. Available online: https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt---convalescent-plasma-2022-02-03.pdf (accessed on 1 April 2022).
- Prati, D.; Fiorin, F.; Berti, P.; De Silvestro, G.; Accorsi, P.; Ostuni, A. Italian Society for Transfusion Medicine and Immunohaematology (SIMTI), and the Italian Society for Haemapheresis and Cell Manipulation (SIdEM). Position paper on the use of COVID-19 convalescent plasma: An update. Blood Transfus. 2021, 19, 277–280. [Google Scholar]
- Franchini, M.; Cruciani, M. How Safe Is COVID-19 Convalescent Plasma? Mayo Clin. Proc. 2021, 96, 2279–2281. [Google Scholar] [CrossRef]
- Senefeld, J.W.; Johnson, P.W.; Kunze, K.L.; Bloch, E.M.; van Helmond, N.; Golafshar, M.A.; Klassen, S.A.; Klompas, A.M.; Sexton, M.A.; Soto, J.C.D.; et al. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Med. 2021, 18, e1003872. [Google Scholar] [CrossRef]
- Focosi, D.; Franchini, M.; Pirofski, L.-A.; Burnouf, T.; Paneth, N.; Joyner, M.J.; Casadevall, A. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin. Microbiol. Rev. 2022, 9, e0020021. [Google Scholar] [CrossRef]
- FDA. Available online: https://www.fda.gov/media/141477/download (accessed on 1 April 2022).
- Franchini, M.; Glingani, C.; De Donno, G.; Lucchini, G.; Beccaria, M.; Amato, M.; Castelli, G.P.; Bianciardi, L.; Pagani, M.; Ghirardini, M.; et al. Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience. Life 2022, 12, 420. [Google Scholar] [CrossRef]
- De Silvestro, G.; Marson, P.; La Raja, M.; Cattelan, A.M.; Guarnieri, G.; Monticelli, J.; Tiberio, I.; Vianello, A.; Gandini, G.; Gessoni, G.; et al. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry. Eur. J. Intern. Med. 2021, 97, 42–49. [Google Scholar] [CrossRef]
- Ferrari, S.; Caprioli, C.; Weber, A.; Rambaldi, A.; Lussana, F. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk. Lymphoma 2021, 62, 1490–1496. [Google Scholar] [CrossRef]
- Menichetti, F.; Popoli, P.; Puopolo, M.; Alegiani, S.S.; Tiseo, G.; Bartoloni, A.; TSUNAMI Study Group. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Netw. Open. 2021, 4, e2136246. [Google Scholar] [CrossRef]
- Franchini, M.; Focosi, D.; Casadevall, A.; Joyner, M.J.; Perotti, C. Convalescent plasma for COVID-19. TSUNAMI is not the final word. Eur. J. Intern. Med. 2022, 97, 116–118. [Google Scholar] [CrossRef]
- Italian Ministry of Health. COVID-19 in Italy. Available online: https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?lingua=english&id=5367&area=nuovoCoronavirus&menu=vuoto (accessed on 1 April 2022).
- Franchini, M.; Glingani, C.; Morandi, M.; Corghi, G.; Cerzosimo, S.; Beduzzi, G.; Storti, A.; Di Stasi, V.; Rastrelli, G.; Vignozzi, L.; et al. Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial. Mayo Clin. Proc. Innov. Qual. Outcomes 2021, 5, 403–412. [Google Scholar] [CrossRef]
- Focosi, D.; Franchini, M. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. Transfus. Clin. Biol. 2021, 28, 132–134. [Google Scholar] [CrossRef]
- Franchini, M.; Marano, G.; Velati, C.; Pati, I.; Pupella, S.; Liumbruno, G.M. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy. Vox Sang. 2020, 116, 136–137. [Google Scholar] [CrossRef]
- Accorsi, P.; Berti, P.; de Angelis, V.; De Silvestro, G.; Mascaretti, L.; Ostuni, A. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19. Transfus. Apher. Sci. 2020, 59, 102817. [Google Scholar] [CrossRef]
- Gaiarsa, S.; Giardina, F.; Biffignandi, G.B.; Ferrari, G.; Piazza, A.; Tallarita, M.; Baldanti, F. Comparative analysis of SARS-CoV-2 quasispecies in the upper and lower respiratory tract shows an ongoing evolution in the spike cleavage site. Virus Res. 2022, 315, 198786. [Google Scholar] [CrossRef]
- Sammartino, J.C.; Cassaniti, I.; Ferrari, A.; Giardina, F.; Ferrari, G.; Zavaglio, F.; Paolucci, S.; Lilleri, D.; Piralla, A.; Baldanti, F.; et al. Evaluation of the Neutralizing Antibodies Response against 14 SARS-CoV-2 Variants in BNT162b2 Vaccinated Naïve and COVID-19 Positive Healthcare Workers from a Northern Italian Hospital. Vaccines 2022, 10, 703. [Google Scholar] [CrossRef]
- Reed, L.J.; Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27, 493–497. [Google Scholar]
- Percivalle, E.; Cambiè, G.; Cassaniti, I.; Nepita, E.V.; Maserati, R.; Ferrari, A. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi red Zone in Lombardy, Italy, as at 06 April 2020. Eurosurveillance 2020, 25, 2001031. [Google Scholar] [CrossRef]
- Franchini, M.; Focosi, D.; Mengoli, C.; Percivalle, E.; Sammartino, J.C.; Ferrari, A.; Zani, M.; Glingani, C.; Baldanti, F. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors. Transfusion 2022, 62, 1171–1176. [Google Scholar] [CrossRef]
- Ordaya, E.E.; Abu Saleh, O.M.; Stubbs, J.R.; Joyner, M.J. Vax-Plasma in Patients With Refractory COVID-19. Mayo Clin. Proc. 2022, 97, 186–189. [Google Scholar] [CrossRef]
- Alteri, C.; Cento, V.; Piralla, A.; Costabile, V.; Tallarita, M.; Colagrossi, L.; Renica, S.; Giardina, F.; Novazzi, F.; Gaiarsa, S.; et al. Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy. Nat. Commun. 2021, 12, 434. [Google Scholar] [CrossRef]
- Casari, S.; Lucchini, G.; Burato, E.; Bertoletti, R.; Boscaini, R.; Bellani, A.; Lombardi, L.; Benedini, N.; Firriolo, E.; Vallicella, F.; et al. The COVID-19 Epidemic: The experience in the Social and Health Care Center of the Mantua District (Lombardy Region, Northern Italy). Epidemiol. Prev. 2021, 45, 559–567. [Google Scholar]
- Destras, G.; Bal, A.; Simon, B.; Lina, B.; Josset, L. Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patients. Lancet Microbe 2022. [Google Scholar] [CrossRef]
CCP Donorno. | Sex | Age (Years) | CCP Donation (m/d/y) | COVID-19 Vaccine | Anti-SARS-CoV-2 nAb Titer | Days between CCP Donation and | VOC Lineage | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Type | Doses | Last Dose (Month/Day/Year) | Anti-Wild Type | Anti- B.1.617.2 | Anti- B.1.1.529 | Last Vaccine Dose | COVID-19 Recovery | |||||
1 | M | 53 | 10/06/2021 | AZ | 2 | 06/09/2021 | 640 | 320 | 10 | 119 | 13 | B.1.617.2 |
2 | M | 56 | 10/20/2021 | AZ | 1 | 05/15/2021 | 640 | 80 | <10 | 158 | 89 | B.1.617.2 |
3 | M | 27 | 10/27/2021 | AZ | 2 | 05/15/2021 | 640 | 160 | 10 | 165 | 141 | B.1.617.2 |
4 | F | 35 | 10/27/2021 | Pfizer | 1 | 06/26/2021 | 160 | 40 | <10 | 123 | 70 | B.1.617.2 |
5 | M | 46 | 10/27/2021 | J&J | 1 | 06/06/2021 | 640 | 160 | 10 | 143 | 19 | B.1.617.2 |
6 | M | 20 | 11/10/2021 | Pfizer | 1 | 06/20/2021 | 320 | 160 | 10 | 143 | 82 | B.1.617.2 |
7 | F | 52 | 11/10/2021 | Pfizer | 2 | 03/10/2021 | 640 | 320 | 40 | 245 | 71 | B.1.617.2 |
8 | M | 35 | 11/17/2021 | Pfizer | 1 | 02/02/2021 | 640 | 640 | 40 | 288 | 54 | B.1.617.2 |
9 | M | 53 | 11/24/2021 | AZ | 1 | 06/07/2021 | 20 1 | 10 1 | 10 1 | 170 | 91 | B.1.617.2 |
10 | M | 58 | 12/01/2021 | Pfizer | 2 | 07/06/2021 | 160 | 80 | <10 | 148 | 20 | B.1.617.2 |
11 | M | 46 | 12/10/2021 | Pfizer | 2 | 07/18/2021 | 320 | 160 | 10 | 145 | 21 | B.1.617.2 |
12 | M | 51 | 12/10/2021 | J&J | 1 | 06/07/2021 | 640 | 320 | 20 | 186 | 35 | B.1.617.2 |
13 | M | 28 | 12/15/2021 | AZ | 2 | 05/31/2021 | 320 | 640 | 40 | 198 | 23 | B.1.617.2 |
14 | M | 53 | 12/16/2021 | AZ | 2 | 06/09/2021 | 640 | 160 | 10 | 190 | 84 | B.1.617.2 |
15 | M | 26 | 12/22/2021 | J&J | 1 | 06/30/2021 | 640 | 640 | 40 | 175 | 27 | B.1.617.2 |
16 | F | 47 | 12/27/2021 | Pfizer | 2 | 06/10/2021 | NP | 320 | 40 | 200 | 14 | B.1.617.2 |
17 | M | 51 | 12/27/2021 | AZ | 2 | 06/09/2021 | NP | 640 | 160 | 201 | 26 | B.1.617.2 |
19 | M | 26 | 01/05/2022 | Pfizer | 2 | 08/05/2021 | NP | 640 | 10 | 153 | 21 | B.1.617.2 |
19 | M | 59 | 01/05/2022 | Pfizer | 2 | 06/26/2021 | NP | 640 | <10 | 193 | 149 | B.1.617.2 |
20 | M | 40 | 02/08/2022 | Pfizer | 2 | 10/29/2021 | NP | 640 | 160 | 105 | 22 | B.1.1.529 |
21 | M | 57 | 02/08/2022 | Pfizer | 3 | 10/26/2021 | NP | 640 | 320 | 102 | 18 | B.1.1.529 |
22 | M | 57 | 02/11/2022 | Pfizer (2)/AZ (1) | 3 | 11/29/2021 | NP | 640 | 640 | 74 | 36 | B.1.1.529 |
23 | M | 56 | 02/16/2022 | Pfizer (2)/Moderna (1) | 3 | 12/18/2021 | NP | 640 | 160 | 60 | 21 | B.1.1.529 |
24 | M | 55 | 02/17/2022 | Pfizer (2)/AZ (1) | 3 | 12/03/2021 | NP | 320 | 40 | 76 | 22 | B.1.1.529 |
25 | M | 56 | 02/18/2022 | Pfizer (2)/AZ (1) | 3 | 01/20/2022 | NP | 160 | 80 | 29 | 18 | B.1.1.529 |
26 | M | 34 | 02/21/2022 | Pfizer (2)/Moderna (1) | 3 | 01/12/2022 | NP | 640 | 160 | 40 | 19 | B.1.1.529 |
27 | M | 51 | 02/24/2022 | J&J (1)/Moderna (2) | 3 | 12/23/2021 | NP | 320 | 160 | 63 | 32 | B.1.1.529 |
28 | M | 40 | 03/11/2022 | Pfizer | 3 | 07/17/2021 | NP | 160 | 20 | 237 | 24 | B.1.1.529 |
29 | M | 24 | 03/15/2022 | Pfizer (2)/Moderna (1) | 3 | 01/13/2022 | NP | 160 | 160 | 61 | 45 | B.1.1.529 |
30 | M | 34 | 03/22/2022 | Pfizer (2)/Moderna (1) | 3 | 12/16/2021 | NP | 640 | 160 | 96 | 17 | B.1.1.529 |
31 | M | 54 | 03/23/2022 | Pfizer (2)/Moderna (1) | 3 | 01/07/2022 | NP | 640 | 320 | 75 | 13 | B.1.1.529 |
32 | M | 38 | 03/25/2022 | Pfizer (2)/Moderna (1) | 3 | 01/21/2022 | NP | 640 | 640 | 63 | 52 | B.1.1.529 |
Pt.no. | Age (Years) | Sex | BMI | COVID-19 Vaccine/Doses | Days Since LastVaccine Dose to COVID-19 | Hospital Admission (m/d/y) | VOC Lineage | COVID-19 Severity/Hospital Department | Comorbidities/Complications | PaO2/FiO2 before CCP Transfusion | Anti-SARS-CoV-2 IgG 1 | Number of CCP Units Transfused/nAb Titer 2 | Days between Symptom Onset and CCP Transfusion | Days between Last CCP Transfusion and VC | Previous/Concomitant Therapies | Outcome 3 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 75 | M | 24 | No | - | 10/29/2021 | B.1.617.2 | Severe/RU | AF, hypertension | 140 | Negative | 3/320 | 14 | 11 | ST, HEP | Alive |
2 | 60 | M | 34 | Pfizer/2 | 160 | 11/16/2021 | B.1.617.2 | Severe/RU | Hypertension, diabetes, CT for thymoma | 156 | Negative | 3/160–320 | 10 | 10 | ST, HEP, REM | Alive |
3 | 52 | M | 33 | No | - | 11/18/2021 | B.1.617.2 | Severe/RICU | CRU, VABP, tracheostomy | 115 | Negative | 3/160 | 6 | 18 | ST, HEP, REM, mAbs 4 | Alive |
4 | 28 | F | 31 | No | - | 11/17/2021 | B.1.617.2 | Severe/RICU | Pituitary adenoma | 95 | Negative | 3/160–640 | 7 | 3 | ST, HEP | Alive |
5 | 50 | F | 29 | No | - | 09/21/2021 | B.1.617.2 | Severe/RU | Hypertension, tracheostomy | 94 | Negative | 1/160 | 9 | 7 | ST, HEP | Alive |
6 | 72 | M | 23 | Pfizer/3 | 98 | 01/08/2022 | B.1.617.2 | Severe/RU | NHL | 118 | Negative | 2/320 | 11 | NA | RTX, ST, HEP | Alive |
7 | 72 | M | 27 | Moderna/3 | 26 | 02/26/2022 | B.1.1.529 | Severe/RU | Diabetes, hypertension | 149 | Negative | 1/640 | 6 | 7 | ST, HEP | Alive |
8 | 78 | M | 35 | AZ/2 | 142 | 11/17/2021 | B.1.617.2 | Severe/RICU | Diabetes, hypertension, PC | 88 | Negative | 2/160 | 18 | NA | ST, HEP | Dead |
9 | 77 | M | 26 | No | - | 12/21/2021 | B.1.617.2 | Severe/RICU | CAD, hypertension, dyslipidemia, LC | 72 | Negative | 2/640 | 19 | NA | ST, HEP | Dead |
10 | 72 | M | 28 | No | - | 12/28/2021 | B.1.617.2 | Severe/RICU | Diabetes, MI, hypertension, FS | 144 | Negative | 2/160–640 | 9 | 4 | ST, HEP | Alive |
11 | 66 | M | 37 | Pfizer/2 | 176 | 12/30/2021 | B.1.617.2 | Severe/RICU | OSAS, diabetes, dyslipidemia, CAD | 91 | Negative | 1/640 | 11 | 10 | ST, HEP | Alive |
12 | 44 | M | 32 | No | - | 01/29/2022 | B.1.1.529 | Severe/ICU | Hypertension, VABP | 122 | Negative | 1/160 | 5 | 9 | ST, HEP | Alive |
13 | 81 | M | 28 | Moderna/1 | 2 | 12/23/2021 | B.1.617.2 | Severe/IMU | Hypertension, CPOA, SCI | 86 | Negative | 1/320 | 6 | NA | ST. HEP | Dead |
14 | 49 | M | 33 | No | - | 12/31/2021 | B.1.617.2 | Severe/IMU | None | 175 | Negative | 1/160 | 10 | 7 | ST, HEP | Alive |
15 | 72 | M | 23 | Pfizer/3 | 42 | 01/12/2022 | B.1.617.2 | Severe/IMU | CLL | 144 | Negative | 2/640 | 9 | NA | ST, HEP, REM, mAbs 4 | Alive |
16 | 61 | F | 21 | No | - | 01/24/2022 | B.1.1.529 | Severe/IMU | None | 117 | Negative | 1/160 | 6 | 4 | ST, HEP, REM | Alive |
17 | 54 | M | 24 | Pfizer/2 | 84 | 01/26/2022 | B.1.1.529 | Severe/IMU | None | 259 | Negative | 1/160 | 8 | 8 | ST, HEP | Alive |
18 | 50 | M | 26 | Moderna/2 | 22 | 01/22/2022 | B.1.1.529 | Severe/IMU | RA, 5 hypertension | 244 | Negative | 1/160 | 11 | 5 | ST, HEP, MTX | Alive |
19 | 74 | F | 22 | Moderna/3 | 153 | 03/03/2022 | B.1.1.529 | Severe/RICU | NHL | 81 | Negative | 2/320 | 1 | NA | ST, HEP, RTX | Alive |
20 | 76 | M | 25 | Pfizer/3 | 144 | 03/16/2022 | B.1.1.529 | Severe/RICU | CLL, CAD, hypertension | 147 | Negative | 2/640 | 3 | 3 | ST, HEP, RTX | Alive |
21 | 6 | M | 14 | No | - | 01/14/2022 | B.1.617.2 | Severe/ICU | PHLH | 230 | Negative | 2/320–640 | 15 | 21 | ST, REM, IVIG, ANA, RUX | Alive |
Parameters | Alive n = 18 (85.7%) | Dead n = 3 (14.3%) | p |
---|---|---|---|
Median age, years (IQR) | 60.5 (50.0–72.0) | 78 (77.5–79.5) | 0.03 |
Sex (males/females), number | 15/3 | 3/0 | - |
Median BMI (kg/m2) (IQR) | 27.0 (24.0–32.0) | 28.0 (27.0–31.5) | NS |
Comorbidities, n (%) <3 ≥3 | 6 (33.3) 12 (66.7) | 0 (0) 3 (100) | - |
PaO2/FiO2, median (IQR) | 138.5 (115.5–154.3) | 86.0 (79.0–87.0) | 0.03 |
Days between symptom onset and CCP therapy, median (IQR) | 9 (6.0–10.8) | 18 (12.0–18.5) | 0.02 |
CCP units transfused, mean (±SD) | 1.8 (±0.8) | 1.7 (±0.6) | NS |
CCP neutralizing titer, mean (±SD) | 360.0 (±203.2) | 384.0 (±242.6) | NS |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Franchini, M.; Focosi, D.; Percivalle, E.; Beccaria, M.; Garuti, M.; Arar, O.; Pecoriello, A.; Spreafico, F.; Greco, G.; Bertacco, S.; et al. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. Viruses 2022, 14, 1443. https://doi.org/10.3390/v14071443
Franchini M, Focosi D, Percivalle E, Beccaria M, Garuti M, Arar O, Pecoriello A, Spreafico F, Greco G, Bertacco S, et al. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. Viruses. 2022; 14(7):1443. https://doi.org/10.3390/v14071443
Chicago/Turabian StyleFranchini, Massimo, Daniele Focosi, Elena Percivalle, Massimiliano Beccaria, Martina Garuti, Omar Arar, Antonietta Pecoriello, Fabio Spreafico, Graziana Greco, Stefano Bertacco, and et al. 2022. "Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients" Viruses 14, no. 7: 1443. https://doi.org/10.3390/v14071443